Cargando…

Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model

We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, M.L., Coyle, D., Le, T., Fung, M. Fung Kee, Wells, G.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002486/
https://www.ncbi.nlm.nih.gov/pubmed/17938699
_version_ 1782135719585644544
author Hopkins, M.L.
Coyle, D.
Le, T.
Fung, M. Fung Kee
Wells, G.
author_facet Hopkins, M.L.
Coyle, D.
Le, T.
Fung, M. Fung Kee
Wells, G.
author_sort Hopkins, M.L.
collection PubMed
description We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care.
format Text
id pubmed-2002486
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-20024862007-10-15 Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model Hopkins, M.L. Coyle, D. Le, T. Fung, M. Fung Kee Wells, G. Curr Oncol Practice Guideline Series We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care. Multimed Inc. 2007-10 /pmc/articles/PMC2002486/ /pubmed/17938699 Text en 2007 Multimed Inc.
spellingShingle Practice Guideline Series
Hopkins, M.L.
Coyle, D.
Le, T.
Fung, M. Fung Kee
Wells, G.
Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title_full Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title_fullStr Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title_full_unstemmed Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title_short Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
title_sort cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
topic Practice Guideline Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002486/
https://www.ncbi.nlm.nih.gov/pubmed/17938699
work_keys_str_mv AT hopkinsml cancerantigen125inovariancancersurveillanceadecisionanalysismodel
AT coyled cancerantigen125inovariancancersurveillanceadecisionanalysismodel
AT let cancerantigen125inovariancancersurveillanceadecisionanalysismodel
AT fungmfungkee cancerantigen125inovariancancersurveillanceadecisionanalysismodel
AT wellsg cancerantigen125inovariancancersurveillanceadecisionanalysismodel